Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul-Sep;11(3):142-147.
doi: 10.4103/japtr.JAPTR_18_20. Epub 2020 Jul 14.

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect

Hayder M Al-Kuraishy  1 , Oula Mohamed Sami  1 , Nawar R Hussain  1 , Ali I Al-Gareeb  1
Affiliations

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect

Hayder M Al-Kuraishy et al. J Adv Pharm Technol Res. 2020 Jul-Sep.

Abstract

The aim of the present study was to investigate the probable effects of metformin plus vildagliptin on the oxidative stress index (OSI) in patients with type II diabetes mellitus (T2DM). In this case-control study, 44 patients with T2DM on either metformin monotherapy (n = 24) or metformin plus vildagliptin (n = 20) were compared with healthy controls (n = 20). Anthropometric and biochemical variables including body mass index, blood pressure profile, cardiac indices, lipid profile, fasting blood glucose, fasting serum insulin, and glycemic indices were assessed. Besides, total oxidant status (TOS), total antioxidant status (TAS), and OSI were determined. Patients with T2DM have higher risk of cardiometabolic changes compared with the control (P = 0.0001). TAS was lower while TOS and OSI were higher in patients with T2DM, as compared with the healthy controls (P < 0.001). TAS, TOS, and OSI were better in patients with T2DM on metformin plus vildagliptin therapy as compared with metformin monotherapy (P < 0.05). Therefore, this study concluded that metformin plus vildagliptin therapy is more effective than metformin monotherapy in attenuation of OSI in patients with T2DM.

Keywords: Oxidative stress index; total antioxidant status; total oxidant status; type II diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Consort flow diagram
Figure 2
Figure 2
Oxidative stress index in patients with type II diabetes mellitus regarding the effects of diabetic pharmacotherapy. ∗P < 0.05 as compared to metformin monotherapy, ∗∗P < 0.01 as compared to the controls, P< 0.05 as compared to the controls
See this image and copyright information in PMC

References

    1. Al-Kuraishy HM, Al-Gareeb AI, Shams HA, Al-Mamorri F. Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus. J Lab Physicians. 2019;11:317–22. - PMC - PubMed
    1. Dass AS, Narayana S, Venkatarathnamma PN. Effect of Vitamin E and omega 3 fatty acids in type 2 diabetes mellitus patients. J Adv Pharm Technol Res. 2018;9:32–6. - PMC - PubMed
    1. Lella M, Indira K. A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. J Adv Pharm Technol Res. 2013;4:166–70. - PMC - PubMed
    1. Hussien NR, Al-Naimi MS, Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI. Sulfonylurea and neuroprotection: The bright side of the moon. J Adv Pharm Technol Res. 2018;9:120–3. - PMC - PubMed
    1. Abdul-Hadi M, Naji M, Shams H, Sami O, Al-Kuraishy H, Al-Gareeb A. Erectile dysfunction and type 2 diabetes mellitus: A new twist. Int J Nutr Pharmacol Neurol Dis. 2020;10:43–9.